Cytovale is a leading US based diagnosis company pioneering a new class of biomarkers for the diagnosis of fast moving diseases such as Sepsis.
Fast results provide emergency department doctors with an immediate opportunity to decide how to proceed with treatment.
The company’s new technologies include Microfluidics, Precision Imaging and Machine Learning that will provide foundational insights into the roots of immune-mediated disease.
According to the World Health Organisation (WHO), Sepsis causes 20% of global deaths, and estimates that the life-threatening reaction to infection causes 1 in 5 deaths worldwide. Mortality from Sepsis increases as much as 8% for every hour that treatment is delayed.
Product:
Intellisep™ test
Quickly and accurately reveals immune activation at the root of Sepsis. The results are available in less than 10 minutes. The test requires a blood sample from the patient which is then processed in a benchtop instrument designed by the company to sit in hospitals’ clinical laboratories.
